Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:ACTUNASDAQ:ANABNASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.29-1.5%$3.28$2.63▼$4.73$629.97M1.45989,060 shs536,886 shsACTUActuate Therapeutics$8.95-1.0%$7.46$5.51▼$11.73$174.81MN/A47,231 shs129,997 shsANABAnaptysBio$20.70+0.4%$17.90$12.21▼$41.31$634.81M-0.09597,811 shs306,123 shsXERSXeris Biopharma$4.31+0.7%$4.50$1.69▼$6.07$663.48M1.371.88 million shs1.62 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+3.09%+6.03%-0.89%+0.60%+21.45%ACTUActuate Therapeutics+0.44%+13.00%+18.64%-10.58%+903,999,900.00%ANABAnaptysBio+0.93%+0.29%+11.77%+22.31%+6.95%XERSXeris Biopharma+3.63%+4.14%-27.09%+24.06%+143.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma1.8667 of 5 stars3.50.00.00.02.52.50.6ACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AANABAnaptysBio2.451 of 5 stars4.40.00.00.02.71.70.6XERSXeris Biopharma4.2036 of 5 stars4.41.00.04.23.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5067.17% UpsideACTUActuate Therapeutics 3.00Buy$20.50129.05% UpsideANABAnaptysBio 2.70Moderate Buy$33.6362.44% UpsideXERSXeris Biopharma 2.80Moderate Buy$6.1041.53% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, ANAB, XERS, and ABUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/26/2025ANABAnaptysBioJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/7/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $6.003/7/2025XERSXeris BiopharmaCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.503/7/2025XERSXeris BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $4.003/7/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.60 ➝ $8.003/5/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$36.00 ➝ $42.003/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$22.00 ➝ $22.003/3/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M102.09N/AN/A$0.63 per share5.22ACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AANABAnaptysBio$91.28M6.95N/AN/A$3.32 per share6.23XERSXeris Biopharma$203.07M3.27N/AN/A($0.05) per share-86.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.38N/AN/AN/A-1,137.65%-68.18%-51.55%5/1/2025 (Estimated)ACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/AANABAnaptysBio-$163.62M-$5.21N/AN/AN/A-289.75%-287.94%-37.25%5/8/2025 (Estimated)XERSXeris Biopharma-$62.26M-$0.38N/AN/AN/A-33.69%N/A-17.38%5/8/2025 (Estimated)Latest ACTU, ANAB, XERS, and ABUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ANABAnaptysBio-$1.30N/AN/AN/A$15.27 millionN/A5/8/2025Q1 2025XERSXeris Biopharma-$0.07N/AN/AN/A$57.61 millionN/A5/1/2025Q1 2025ABUSArbutus Biopharma-$0.09N/AN/AN/A$2.54 millionN/A3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million2/27/2025Q4 2024ANABAnaptysBio-$1.61-$0.72+$0.89-$0.72$10.17 million$43.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AACTUActuate TherapeuticsN/AN/AN/AN/AN/AANABAnaptysBioN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02ACTUActuate TherapeuticsN/A1.681.68ANABAnaptysBioN/A10.2310.23XERSXeris BiopharmaN/A1.791.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ACTUActuate TherapeuticsN/AANABAnaptysBioN/AXERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%ACTUActuate Therapeutics69.34%ANABAnaptysBio33.70%XERSXeris Biopharma4.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.48 million181.91 millionOptionableACTUActuate Therapeutics1019.53 millionN/AN/AANABAnaptysBio10030.67 million20.17 millionOptionableXERSXeris Biopharma290153.94 million142.28 millionOptionableACTU, ANAB, XERS, and ABUS HeadlinesRecent News About These CompaniesIs Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?April 23 at 12:04 AM | msn.comJPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 22 at 3:10 AM | marketbeat.comRenaissance Technologies LLC Raises Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 21, 2025 | marketbeat.comEAM Investors LLC Buys New Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 20, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 4.9% - Here's What HappenedApril 18, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short InterestApril 18, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Shares Up 4.9% - What's Next?April 17, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest UpdateApril 17, 2025 | americanbankingnews.comKennedy Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 16, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc.April 16, 2025 | marketbeat.comCenterBook Partners LP Sells 2,791,929 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 12, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's WhyApril 3, 2025 | marketbeat.comAIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)March 31, 2025 | marketbeat.comXeris Announces Changes to Its Board of DirectorsMarch 28, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comXeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - Still a Buy?March 25, 2025 | marketbeat.comStrength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?March 20, 2025 | zacks.com12 Best Stocks to Invest in for a Stock Market GameMarch 20, 2025 | insidermonkey.comXeris enters a whole new market for one of its main pharma offeringsMarch 20, 2025 | chicagobusiness.comXeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market GameMarch 19, 2025 | insidermonkey.comCalculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)March 18, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Intel-Taiwan Semiconductor Alliance Fuels Turnaround HopesBy Jeffrey Neal Johnson | April 8, 2025View Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomBy Nathan Reiff | April 10, 2025View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomThe Ecosystem Edge: Joby's Competitive AdvantageBy Jeffrey Neal Johnson | April 4, 2025View The Ecosystem Edge: Joby's Competitive AdvantageGoodyear Gains Traction: Shares Climb as Key Catalysts AlignBy Jeffrey Neal Johnson | April 7, 2025View Goodyear Gains Traction: Shares Climb as Key Catalysts AlignACTU, ANAB, XERS, and ABUS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.29 -0.05 (-1.50%) Closing price 04:00 PM EasternExtended Trading$3.32 +0.03 (+0.91%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Actuate Therapeutics NASDAQ:ACTU$8.91 -0.13 (-1.44%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.AnaptysBio NASDAQ:ANAB$20.70 +0.09 (+0.44%) Closing price 04:00 PM EasternExtended Trading$19.94 -0.76 (-3.67%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Xeris Biopharma NASDAQ:XERS$4.31 +0.03 (+0.70%) Closing price 04:00 PM EasternExtended Trading$4.28 -0.03 (-0.81%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
